Related Experiment Video
Updated: Jan 3, 2026
10:26
Author Spotlight: A Cost-Effective Genomic Workflow for Advancing Rabies Control in Resource-Limited Settings
Published on: August 18, 2023
6.8K
Molecular Pharming for low and middle income countries
Sheeba Murad1, Sebastian Fuller1, Jonathan Menary1
1Institute for Infection and Immunity, St. George's University of London, SW18 0RE, London, UK.
Current Opinion in Biotechnology
|November 22, 2019
Summary
Molecular Pharming offers significant benefits to Low and Middle Income Countries (LMICs), but adoption faces challenges beyond technical feasibility. Academic research must address these real-world concerns to support LMIC development.
Area of Science:
- Biotechnology
- Plant biotechnology
- Molecular farming
Background:
- Molecular Pharming (MP) holds promise for Low and Middle Income Countries (LMICs).
- Adoption of MP in LMICs is slower than in developed nations due to external factors.
- Emerging interest from LMICs in MP is evident.
Purpose of the Study:
- To identify key issues in establishing Molecular Pharming manufacturing capacity in LMICs.
- To analyze concerns and challenges hindering MP adoption in LMICs.
- To guide academic research to better support MP development in LMICs.
Main Methods:
- Case study analysis of Thailand, South Africa, and Brazil.
- Examination of investment considerations for MP manufacturing.
- Identification of gaps between academic research and practical implementation.
Main Results:
- MP adoption in LMICs is complex, involving factors beyond technical feasibility.
- Key issues arise during investment decisions for MP manufacturing capacity.
- Current academic research does not fully address these practical concerns.
Conclusions:
- Understanding LMIC-specific concerns is crucial for successful MP implementation.
- Academic research needs to align with practical challenges to aid MP development in LMICs.
- Targeted research efforts can accelerate the benefits of Molecular Pharming for LMICs.
Related Concept Videos
01:02Prescription, Nonprescription and Orphan Drugs
1.1K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.1K
01:26Drug Discovery: Overview
10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
01:29Microorganisms in Medicine and Therapeutics
893
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
893
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
124
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
124
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
141
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
141
01:26Pharmaceutical Equivalents
161
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
161